CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

**POLICY TYPE**
Parliamentary submission

**DATE**
2022-05-13

**TOPICS**
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

**Documents**

CMA Recommendations on Vaccine Equity and Intellectual Property

House of Commons Standing Committee on Foreign Affairs and International Development
May 11, 2022
https://policybase.cma.ca/link/policy14443

POLICY TYPE  Policy endorsement
DATE          2021-06-24
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs
               Population health, health equity, public health
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE          2020-08-13
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE: Response to consultation
DATE: 2019-05-24
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE Policy document
LAST REVIEWED 2019-03-03
DATE 2010-12-04
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

Summary

The Canadian Medical Association (CMA) recognizes the wide range of regulatory controls now in place to manage the production, distribution, and sale of cannabis for medical use. The CMA supports federal legislation that empowers provinces and territories to develop regulations unique to their needs. The CMA recognizes the importance of ensuring access to cannabis for medical purposes through free and independent clinical assessment.

Recommendations

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. The CMA recommends that the federal government make funding available to support rigorous scientific research to establish the medical efficacy of cannabis and to determine appropriate indications for the use of cannabis.
2. Support the development of a regulatory framework that maintains patient safety and public health. The CMA encourages the federal government to work with provinces and territories to develop a regulatory framework that ensures patient safety and public health.
3. Increase support for public education on the use of cannabis for medical purposes. The CMA encourages the federal government to increase funding for public education initiatives to ensure that the public has access to reliable and accurate information about the use of cannabis for medical purposes.

CMA Policybase - Canadian Medical Association
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2011-05-28

REPLACES
Medication use and seniors

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE       2019-02-20
TOPICS   Pharmaceuticals, prescribing, cannabis, drugs
          Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA CONSULTATION ON CANADIAN DRUGS AND SUBSTANCES STRATEGY

November 1, 2018
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE
Response to consultation

DATE
2018-10-02

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA submission:
IMPLEMENTATION OF NATIONAL PHARMACARE

Submission to the Advisory Council
September 2018
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image of document cover]
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE  
Policy endorsement

DATE  
2018-08-30

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-08-14</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

CMA response: HEATH CANADA CONSULTATION ON REGULATORY AMENDMENTS REGARDING TRAMADOL

August 14, 2018
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE  Parliamentary submission
DATE  2018-04-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE  Parliamentary submission
DATE  2018-02-15
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents

CMA Submission:
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the House of Commons Standing Committee on Health

February 15, 2018
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE Response to consultation
DATE 2017-12-07
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents